Literature DB >> 9697077

Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists.

E A van Schaick1, H J de Greef, A P Ijzerman, M Danhof.   

Abstract

The relationship between blood concentrations of the adenosine A1-receptor agonist N6-(p-sulfophenyl) adenosine (SPA) and its effect on both plasma nonesterified fatty acid (NEFA) and glycerol release was described on the basis of an integrated pharmacokinetic-pharmacodynamic model. An indirect response model rather than a hypothetical "link" model was used to account for the delayed response. For that purpose an empirical solution to the differential equation describing the physiological indirect response model is presented. The model-estimated rate constant for the output of the glycerol response was compared to the elimination rate constant after exogenous administration of glycerol. In a crossover designed study, chronically cannulated male Wistar rats were subjected to either SPA administration (120 microgram/kg for 15 min) for measurement of the effects on glycerol, or glycerol administration for determination of glycerol pharmacokinetics. Glycerol pharmacokinetics was determined in the presence of a stable level of SPA (171 +/- 6 ng/ml) to suppress endogenous glycerol levels completely. The indirect response model adequately described the relationship between SPA concentrations and plasma glycerol levels. The PD parameter estimates for EC50, EMAX, and Hill factor were 23 +/- 2 ng/ml, 74 +/- 3% (change from baseline), and 3.3 +/- 0.5, respectively. These values were not different from those obtained when analyzing the data on basis of the differential equation directly. Furthermore, the EC50 values for the reduction in glycerol or NEFA levels were identical (23 +/- 2 and 21 +/- 3 ng/ml, respectively) indicating that both PD endpoints reflect the same physiological process. The concentration-time profile after administration of glycerol could be described best on the basis of a biexponential function. The value for kout in the PK/PD model (0.19 +/- 0.03 min-1) corresponded very well to the terminal elimination rate constant determined after i.v. administration of glycerol (0.25 +/- 0.03 min-1). In conclusion, the antilipolytic effects of adenosine A1-receptor agonists can be described by the indirect suppression model. The rate constant describing the delay between concentration and glycerol effect was shown to be a true reflection of the removal of glycerol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9697077     DOI: 10.1023/a:1025777700413

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  24 in total

1.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

2.  Pharmacokinetics and pharmacodynamics of prednisolone in obese rats.

Authors:  A I Nichols; R D'Ambrosio; N A Pyszczynski; W J Jusko
Journal:  J Pharmacol Exp Ther       Date:  1989-09       Impact factor: 4.030

3.  Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3',5'-AMP levels and lipolysis.

Authors:  U Schwabe; R Ebert; H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators.

Authors:  C Londos; R C Honnor; G S Dhillon
Journal:  J Biol Chem       Date:  1985-12-05       Impact factor: 5.157

Review 5.  Adenosine receptor subtypes.

Authors:  M G Collis; S M Hourani
Journal:  Trends Pharmacol Sci       Date:  1993-10       Impact factor: 14.819

6.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

7.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

8.  What if Minkowski had been ageusic? An alternative angle on diabetes.

Authors:  J D McGarry
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

9.  Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.

Authors:  S K Yamashita; E A Ludwig; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

10.  Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.

Authors:  K A Jacobson; O Nikodijevic; X D Ji; D A Berkich; D Eveleth; R L Dean; K Hiramatsu; N F Kassell; P J van Galen; K S Lee
Journal:  J Med Chem       Date:  1992-10-30       Impact factor: 7.446

View more
  5 in total

1.  Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Note: caution in use of empirical equations for pharmacodynamic indirect response models.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

3.  Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.

Authors:  A Cleton; H J de Greef; P M Edelbroek; R A Voskuyl; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

4.  Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats.

Authors:  Jing Fang; Debra C DuBois; Yang He; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-11       Impact factor: 2.745

5.  Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations.

Authors:  Selvadurai Muralidharan
Journal:  ISRN Pharm       Date:  2012-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.